Next week, on July 9, Navi Mumbai-based pharmaceutical and nutraceutical product manufacturer Asston Pharmaceuticals is going to launch its Initial Public Offering (IPO). Rs 115 to Rs 123 per share is the price band of this IPO. This public issue will close on July 11, while the last date for IPO share allotment has been fixed as July 14.
Asston shares will be available for trading on the BSE SME platform from July 16. This Rs 27.56 crore IPO is entirely based on 22.41 lakh fresh issues. This means that the entire amount raised from the IPO will be received by the company.
The total outstanding debt on the company as of May 2025 was ₹7.8 crore. Currently, the company's production facility is located in Ambarnath (Maharashtra), where generic and nutraceutical medicines are manufactured. Also, the company has registered trademarks for more than 150 pharmaceutical formulations. The merchant banker for the IPO of Asston Pharmaceuticals will be Sobhagya Capital Options.
Asston Pharmaceuticals, founded in 2019, will use the Rs 6 crore raised from the IPO to purchase machinery for its manufacturing unit, while Rs 13 crore will be spent on meeting working capital requirements. Apart from this, the company will also use the amount to repay debt of Rs 1 crore, and the remaining amount will be used for general corporate purposes.
The bio of Asston Pharmaceuticals' website reads, "is a leading pharmaceuticals company established in 2019 by the Promoters Dr. Ashish Sakalkar, Mrs. Saili More & Mr. Sachin Badakh have experience of over 25 years in the pharma industry for exporting of Healthcare Products to various countries. We supply pharmaceuticals &Healthcare products in the form of Tablets, Capsules, Sachets & Syrup."
